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Abstract 
 
This European Resuscitation Council (ERC) Guidelines for Resuscitation 2018 update is 
focused on the role of antiarrhythmic drugs during advanced life support for cardiac arrest 
with shock refractory ventricular fibrillation/pulseless ventricular tachycardia in adults, 
children and infants. This update follows the publication of the International Liaison 
Committee on Resuscitation (ILCOR) 2018 International Consensus on Cardiopulmonary 
Resuscitation and Emergency Cardiovascular Care Science with Treatment 
Recommendations (CoSTR). The ILCOR CoSTR suggests that any beneficial effects of 
amiodarone or lidocaine are similar. This ERC update does not make any major changes to 
the recommendations for the use of antiarrhythmic drugs during advanced life support for 
shock refractory cardiac arrest. 
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[h1]Introduction 
 
This is the second European Resuscitation Council (ERC) guidelines update following the 
decision by the International Liaison Committee on Resuscitation (ILCOR) to move to a 
continuous evidence evaluation process.1-3 This update follows the publication of the ILCOR  
2018 International Consensus on Cardiopulmonary Resuscitation and Emergency 
Cardiovascular Care Science with Treatment Recommendations (CoSTR) Summary.4 The 
2018 ILCOR CoSTR focused on the use of antiarrhythmic drugs to treat cardiac arrest with a 
shockable rhythm in adults, children and infants and provides an update to the ILCOR 2015 
Advanced Life Support (ALS) and Paediatric CoSTRs.5,6 This topic was prioritised by ILCOR 
following the publication of a large randomised controlled trial (RCT) that compared 
amiodarone, lidocaine and placebo (ALPS) in out-of-hospital cardiac arrest (OHCA) patients 
with shock refractory ventricular fibrillation/pulseless ventricular tachycardia (VF/pVT)7. Here 
the ERC updates the 2015 ALS and Paediatric guidelines on the use of antiarrhythmic drugs 
during cardiopulmonary resuscitation (CPR) and immediately after return of spontaneous 
circulation (ROSC).8,9  
 
[h1]Background 
The primary treatment for cardiac arrest with a shockable rhythm (VF/pVT) is early 
defibrillation and, if required, high-quality chest compressions with minimum interruption.3,10  
Approximately 20% of adult cardiac arrests (in and out-of-hospital) have a shockable rhythm 
when first monitored.11-13 Current guidelines recommend that those patients not responding 
to defibrillation attempts for a primary shockable rhythm, or a non-shockable rhythm that 
turns shockable require an antiarrhythmic drug, with the aim of increasing defibrillation 
success with subsequent defibrillation attempts. In a large OHCA RCT of continuous versus 
interrupted chest compressions, 22.5% of patients had an initial monitored rhythm of VF/pVT 
and about 6.7% received an antiarrhythmic drug.11 For in-hospital cardiac arrest (IHCA), the 
Get With The Guidelines–Resuscitation registry data show that about 18% of adult patients 
had an initial monitored rhythm of VF/pVT, and about 25% received an antiarrhythmic 
drug.12  Shockable rhythms are less common in paediatric cardiac arrest and the incidence 
varies with age (OHCA 1% to 6% in under 5 years-old and 15-20% in adolescence, IHCA 
9% to 14% overall). Only limited data are available on the use of antiarrhythmic drugs after 
paediatric IHCA; about a quarter of cases receive an antiarrhythmic drug.4  Shockable 
rhythms at birth are thought to be extremely rare. However, the lack of heart rhythm 
monitoring during most resuscitation at birth means that data is sparse. Arrests due to 
shockable rhythms do occur after birth in the neonatal period.   
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This update focuses only on the use of antiarrhythmic drugs, but it is likely that other 
interventions have a role in some patients with a refractory shockable cardiac arrest. 
Observational data suggest that successful resuscitation in some patients may require 
mechanical CPR or extracorporeal CPR (eCPR) to buy time for treatment of the underlying 
cause of cardiac arrest (e.g. percutaneous coronary intervention (PCI) for coronary artery 
occlusion).5,14 The role of eCPR will be considered in the 2019 ILCOR CoSTR and ERC 
Guidelines update.15 
 
[h1] ILCOR CoSTR 2018 
 
The ILCOR CoSTR 2018 addressed the use of antiarrhythmic drugs in adults and children in 
any setting (in-hospital or out-of-hospital) with cardiac arrest and a shockable rhythm 
(VF/pVT) at any time during CPR or immediately after ROSC (defined by consensus as 
within 1 hour of ROSC). The systematic review informing the CoSTR identified 14 adult 
RCTs (16 articles) and 19 non-RCTS (18 adult studies, 1 paediatric study, 22 articles).16 
Given the availability of comparative data from large RCTs, the ILCOR ALS Task Force did 
not include non-RCTs in establishing the confidence in the estimated effect size of 
amiodarone and lidocaine. No RCTs of IHCA were identified.  The ERC considered the 2018 
CoSTR in the context of contemporary resuscitation practice in Europe. Table 1 presents a 
summary of the ILCOR 2018 CoSTR and relevant 2015 ERC guidelines. More detailed 
information is presented below. This update will focus on the use of amiodarone, lidocaine 
and magnesium during cardiac arrest and the use of prophylactic antiarrhythmic drugs 
immediately after ROSC in adults, children and infants.  
 
[h1] Amiodarone and lidocaine use in adult cardiac arrest 
 
As part of this guideline update the ERC surveyed its member National Resuscitation 
Councils (NRCs) regarding the use of antiarrhythmic drugs during CPR. All of the 24 NRCs 
that responded reported that amiodarone was the antiarrhythmic drug used most commonly 
for IHCA. For OHCA, amiodarone was reported as the main antiarrhythmic drug used in 22 
countries, lidocaine was the main antiarrhythmic drug used in one country, and the main 
antiarrhythmic drug used was uncertain in one country.  
 
[h2] ERC Guidelines 2018 
We recommend that amiodarone is given after three defibrillation attempts irrespective of 
whether they are consecutive shocks or interrupted by CPR, or for recurrent VF/pVT during 
cardiac arrest. An antiarrhythmic drug can be used in cases of a primary shockable rhythm, 
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or when a shockable rhythm follows a primary shockable cardiac arrest. Give amiodarone 
300 mg intravenously; a further dose of 150 mg may be given after five defibrillation 
attempts. Lidocaine (100 mg) may be used if amiodarone is not available or a local decision 
has been made to use lidocaine instead of amiodarone. An additional bolus of lidocaine 50 
mg may also be given after five defibrillation attempts.  
 
[h2] ILCOR CoSTR in context of ERC Guidelines  
The main change in the 2018 ILCOR CoSTR is that the weak recommendation based on low 
certainty evidence now applies to both amiodarone or lidocaine.4 In the previous 2015 
CoSTR, amiodarone was given a weak recommendation based on moderate certainty 
evidence and lidocaine was given a weak recommendation based on very-low certainty 
evidence.5  
 
The most commonly used formulation of amiodarone includes polysorbate 80 as a diluent. 
Polysorbate 80 can cause hypotension but its effects during CPR are uncertain4. A newer 
formulation of amiodarone (Nexterone®) includes a different diluent, Captisol® (a sulfobutyl 
ether β-cyclodextrin) instead of polysorbate 80, that is not thought to have any 
haemodynamic effects. The Nexterone® formulation of amiodarone is not currently readily 
available in Europe.  
 
The recent OHCA RCT comparing the Nexterone® formulation of amiodarone, lidocaine or 
placebo in patients with VF/pVT refractory after at least one defibrillation attempt reported no 
difference in survival to discharge or good neurological survival at discharge between the 
three groups.7 Patients receiving lidocaine had a higher incidence of ROSC than placebo 
(amiodarone was similar to placebo). Both amiodarone and lidocaine increased survival to 
hospital admission compared with placebo. In addition, a predefined sub-group analysis 
showed an increase in survival to hospital discharge with amiodarone or lidocaine compared 
with placebo in patients who had a bystander witnessed cardiac arrest. Finally, survival rate 
was also higher with amiodarone than with placebo after EMS-witnessed arrest. The 
previous RCT of amiodarone versus placebo for OHCA refractory to three shocks (ARREST, 
1999) compared amiodarone in polysorbate 80 formulation with polysorbate 80 as the 
placebo and showed an increase in survival to hospital admission with amiodarone.17  The 
previous RCT that showed amiodarone (polysorbate 80 formulation) increased survival to 
hospital admission compared with lidocaine (ALIVE, 2002) also used the amiodarone in 
polysorbate 80 formulation and to help with blinding polysorbate 80 was added to the 
lidocaine.18 The impact of the polysorbate 80 in the comparator groups in the ARREST and 
ALIVE studies is uncertain.   
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The ILCOR ALS Task Force opinion was that any beneficial effects on ROSC for 
amiodarone and lidocaine are similar, and that these drugs are most effective when given 
early after the onset of cardiac arrest. Even when pooled, the available studies lack sufficient 
power to be certain of longer-term benefits, but the risk of harm appears small.  The ILCOR 
ALS Task Force considered an increase in ROSC to be an important outcome. The task 
force did consider that an increase in ROSC could burden healthcare systems without an 
increase in the number of patients surviving to discharge. The task force also considered 
that patients who die after a sustained period of ROSC, and their families, may value ROSC 
as it provides family members with some preparation time before a final declaration of death. 
Patients, families, and society may also value ROSC because among those who 
subsequently die there is the potential to enable organ donation.  
 
A major consideration for leaving the ERC recommendation largely unchanged is that in our 
survey of NRCs, 21 out of 24 respondents stated that amiodarone would remain the main 
antiarrhythmic drug used during CPR despite the evidence suggesting that any beneficial 
effects of amiodarone and lidocaine are similar. The main reasons given for continuing to 
use amiodarone are that amiodarone is readily available, its use is established and widely 
implemented, and any change to lidocaine would have implementation and training issues 
and could cause confusion. This ERC accepts that given the ILCOR CoSTR some NRCs 
may wish to change to lidocaine.  
 
[h1] Magnesium use in adult cardiac arrest in adults  
Magnesium therapy has a role in correcting hypomagnesaemia, hypokalaemia, and during 
the treatment of polymorphic VT (torsade de pointes).8,19 
 
[h2] ERC Guidelines 2018 
The recommendations of the ERC are unchanged in that we recommend magnesium is not 
used routinely for the treatment of cardiac arrest. 
 
[h2] ILCOR CoSTR in context of ERC Guidelines  
The ILCOR CoSTR did not identify any new RCTs published since the 2015 CoSTR. The 
CoSTR does state that there is a role for magnesium in specific circumstances during 
refractory VF/pVT (e.g. hypomagnesemia, torsade de pointes). The existing ERC guidelines 
therefore remain unchanged.8,19 
 
[h1] Prophylactic antiarrhythmic drugs immediately after ROSC in adults 
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[h2] ERC Guidelines 2018 
The ERC has not made any previous recommendation on the prophylactic use of 
antiarrhythmic drugs after a cardiac arrest with a shockable rhythm, and this remains the 
case after the ILCOR 2018 CoSTR.  
 
[h2] ILCOR CoSTR in context of ERC Guidelines  
No new studies of the use of prophylactic antiarrhythmic drugs in patients immediately 
(within 1 hour) after ROSC following a VF/pVT cardiac arrest were identified in the 2018 
ILCOR CoSTR. Observational studies of beta-blocker or lidocaine use after ROSC were 
reviewed in the 2015 ILCOR ALS CoSTR5. These data are of insufficient quality to enable 
any recommendation. This has been identified as a knowledge gap.   
 
[h1] Antiarrhythmic drugs for cardiac arrest in infants and children 
Amiodarone and lidocaine are also the two most commonly used antiarrhythmic drugs used 
during CPR in infants and children. 
 
[h2] ERC Guidelines 2018 
The recommendations of the ERC are unchanged for the use of antiarrhythmic drugs in 
infants and children.9 For VF/pVT give amiodarone 5 mg kg−1 after the third shock once CPR 
has been resumed. Give a second dose of amiodarone 5 mg kg−1 if still in VF/pVT after the 
fifth shock. Lidocaine can be used as an alternative to amiodarone. It can be used with a 
loading dose of 1 mg kg−1 (maximum dose 100 mg/dose) followed by continuous infusion at 
20–50 micrograms kg−1 min−1. In the event a VF/pVT cardiac arrest in the neonatal period, 
these guidelines for infants and children should be followed. 
 
[h2] ILCOR CoSTR in context of ERC Guidelines  
The ERC guidelines are consistent with the 2018 ILCOR CoSTR. The ILCOR Paediatric 
Task Force made a decision not to extrapolate data from adult studies given that most cases 
of adult refractory VF/pVT are associated with coronary artery disease. The basis of the 
paediatric recommendations is a single observational study of IHCA from the Get With The 
Guidelines Registry that was already considered in the 2015 ILCOR CoSTR.6,20 
 
[h1]Conclusion 
 
The ERC acknowledges the quality and rigour of the evidence appraisal conducted by 
ILCOR. The ERC review of the newly gathered evidence on antiarrhythmic drugs does not 
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lead to any immediate changes in the ERC teaching materials, course content or programs. 
The review should enable laypeople and healthcare professionals to be confident that 
guidelines are based on the most up to date evidence.  
 
Implementation of the key messages from Guidelines 2015 with a 2017 and 2018 update 
supports the ERC’s mission to preserve human life by making high-quality resuscitation 
available to all. 
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Table 1 Summary of ILCOR CoSTR and ERC Guidelines 2018 – the role of antiarrhythmic drugs during advanced life support. The Table indicates changes to 
ERC Guidelines and Timescale for implementation.  
 
 
Topic 
 
ILCOR CoSTR 2018 
 
ERC Guideline 2015 
 
ERC 2018 
Guideline 
change  
 
 
Antiarrhythmic 
drugs for 
cardiac arrest 
in adults 
 
We suggest the use of amiodarone or lidocaine in 
adults with shock-refractory VF/pVT (weak 
recommendation, low-certainty evidence).  
 
We suggest against the routine use of magnesium 
in adults with shock-refractory VF/pVT (weak 
recommendation, very low-certainty evidence).  
 
The confidence in effect estimates is currently 
too low to support an ALS Task Force 
recommendation about the use of bretylium, 
nifekalant, or sotalol in the treatment of adults in 
cardiac arrest with shock-refractory 
VF/pVT. 
 
 
We recommend that amiodarone should be given after three 
defibrillation attempts irrespective of whether they are 
consecutive shocks, or interrupted by CPR, or for recurrent 
VF/pVT during cardiac arrest. Give amiodarone 300 mg 
intravenously; a further dose of 150 mg may be given after five 
defibrillation attempts.  
 
Lidocaine (100 mg) may be used as an alternative if amiodarone is 
not available or a local decision has been made to use lidocaine 
instead of amiodarone. An additional bolus of lidocaine 50 mg can 
also be given after five defibrillation attempts. 
 
We recommend that magnesium is not used routinely for the 
treatment of cardiac arrest. 
 
Minor changes 
that show that 
any beneficial 
effects of 
amiodarone and 
lidocaine are 
similar.   
 
Post-
resuscitation 
antiarrhythmic 
drugs in adults 
 
The confidence in effect estimates is currently 
too low to support an ALS Task Force 
recommendation about the use of prophylactic 
antiarrhythmic drugs 
immediately after ROSC in adults with VF/pVT 
cardiac 
arrest. 
 
No specific guidance given  
 
No change 
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Antiarrhythmic 
drugs for 
cardiac arrest 
in infants and 
children  
 
We suggest that amiodarone or lidocaine be used 
in the treatment of paediatric shock-refractory 
VF/pVT (weak recommendation, very low-
certainty evidence). 
 
[For VF/pVT give] amiodarone 5 mg kg−1 after the third shock once 
CPR has been resumed. 
Give a second dose of amiodarone 5 mg kg−1 if still in VF/pVT after 
the fifth shock. 
 
Lidocaine may be used as an alternative to amiodarone. 
It can be used with a loading dose of 1 mg kg−1 (maximum dose 
100 mg/dose) followed by continuous infusion at 20–50 
micrograms kg−1 min−1.  
 
There is no evidence for giving magnesium routinely during 
cardiopulmonary arrest. 
 
 
No change  
Abbreviations: ALS Advanced Life Support, CoSTR Consensus on Science and Treatment Recommendation, ERC European Resuscitation Council, ILCOR 
International Liaison Committee on Resuscitation, ROSC return of spontaneous circulation, VF/pVT ventricular fibrillation/pulseless ventricular tachycardia.  
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